Navigation Links
Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
Date:8/28/2008

e II and five products focused on infectious diseases in preclinical development.

Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

For more information please visit: http://www.intercell.com

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward- looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.


'/>"/>
SOURCE Intercell AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 30, 2015 Research and Markets ... the "Medical Device Studies: Clinical Evidence" ... has been designed specifically for those who are ... devices and in-vitro diagnostic products. Clinical data is ... on high quality, appropriate clinical evidence has grown ...
(Date:4/1/2015)... Respironics, a division of Royal Philips (NYSE: ... mask is now available in the United ... (OSA). Designed to maximize comfort and effectiveness, Pico is the ... available on the market to treat OSA*. Philips Pico, along ... display at Medtrade Spring (Booth #235) in ...
(Date:4/1/2015)... 2015  Egalet Corporation (Nasdaq: EGLT ) ... on developing, manufacturing and marketing innovative pain treatments, ... $60.0 million aggregate principal amount of its convertible ... private placement to qualified institutional buyers pursuant to ... as amended (the "Act"). Egalet also granted the ...
Breaking Medicine Technology:Medical Device Studies: Clinical Evidence Seminar - London, UK, 13th, 14th of May 2015 2Philips Pico CPAP Nasal Mask Now Available in the United States 2Philips Pico CPAP Nasal Mask Now Available in the United States 3Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 2Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 3Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 4Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 5Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 6Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 7
... of Cardiology Continue ... Attention to Innovative Technology, CARLSBAD, Calif., Sept. 2 ... involving its innovative atrial,fibrillation ablation products were presented by ... Netherlands at the European Society of,Cardiology (ESC) congress. One ...
... ALBUQUERQUE, N.M., Sept. 2 Clinical Lab,Products ... BMOD),( http://www.biomoda.com ) and its proprietary early ... more promising advances in the cancer diagnostic,technology. ... makes particular,note of the assay,s simplicity that ...
Cached Medicine Technology:Catheter Ablation System for Atrial Fibrillation Shows Reduced Procedure Time, Remarkable Safety Profile and Excellent Outcomes in Two Clinical Studies 2Catheter Ablation System for Atrial Fibrillation Shows Reduced Procedure Time, Remarkable Safety Profile and Excellent Outcomes in Two Clinical Studies 3Clinical Lab Products Magazine Features Biomoda 2
(Date:4/1/2015)... NTOCC today launches the Knowledge & Resource Center, a ... improve care transitions and positively impact health outcomes. , ... to tools or resources that align with its mission ... through the promotion of public policy, and education and ... the Knowledge & Resource Center serves as a mechanism ...
(Date:4/1/2015)... April 01, 2015 After a particularly harsh ... these potholes can lead to costly damage, so Amica ... Amica is sharing the following suggestions from AAA: , ... tread and be inflated to the manufacturer’s recommended levels. ... handling, excessive vibration and uneven tire wear can be signs ...
(Date:4/1/2015)... York, New York (PRWEB) April 01, 2015 ... housing hundreds of Risperdal lawsuits ( http://www.risperdallawsuit2014.com/ ) ... to the calendar for the Philadelphia Court of Common ... Court Room 206, City Hall. Court records indicate that ... claims filed on behalf of Risperdal users who experienced ...
(Date:4/1/2015)... EAGAN, Minn. (April 1, 2015) —Blue Cross and ... (Blue Cross) today announced audited financial results for 2014. ... of $61.5 million, reflecting positive investment portfolio performance that ... operating loss of $8.2 million on full-year revenues of ... of one percent (0.1%). , Blue Cross reported ...
(Date:4/1/2015)... 2015 Parents of teenaged and adolescent ... where the latest post discusses Teen Violence Related to ... Teen Dating Violence Awareness Month, the substance abuse treatment ... to help parents identify if there may be problems ... involve drugs or alcohol. , “People learn how to ...
Breaking Medicine News(10 mins):Health News:National Transitions of Care Coalition Launches Knowledge & Resource Center 2Health News:National Transitions of Care Coalition Launches Knowledge & Resource Center 3Health News:Prepare for potholes with 7 tips from Amica Insurance 2Health News:Pennsylvania Court Overseeing Hundreds of Risperdal Lawsuits Schedules April Meeting 2Health News:Pennsylvania Court Overseeing Hundreds of Risperdal Lawsuits Schedules April Meeting 3Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 2Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 3Health News:Best Drug Rehabilitation Issues Toolkit for Teen Violence Related to Substance Abuse 2
... hormone replacement therapy because of health concerns surrounding the therapy.// ... hormones, has led to elevated hormone levels in some women ... excessive bleeding, blood clots and increased risk of breast and ... director of the Sydney Menopause Centre at Randwick's Royal Hospital ...
... the AIDS treatment program in Lusaka, Zambia, have explained that ... in its first two years.// ,The leaders made ... International AIDS Conference in Toronto. They explained that their new ... not possible to provide sophisticated AIDS care to patients in ...
... thousands of people who suffer from asthma could be spared ... researchers who had published their findings in the journal Nature ... of anti-viral proteins when suffering a cold as compared to ... reason for their being more likely to suffer a severe ...
... a scheme under which sick and injured Indians sent back ... Dawda, managing director of Al Itefaq Trading LLC, //said he ... who can treat such patients who cannot get access to ... according to the Times of Oman newspaper. ...
... Pepsi Co Saturday offered to work with the Centre ... standards" following charges of pesticide content in its products.// ... soft drink brands of Pepsi and Coca Cola contained ... products are safe and comply with the most stringent ...
... experiment was conducted in the Arizona State University's (ASU) ... the graduate student families //in the cluster of six ... bushes spend time together talking while their kids play ... six homes on native Sonoran desert hardly know each ...
Cached Medicine News:Health News:Women Alerted against "Natural Hormone Replacement Therapy" 2Health News:The Aids Programme In Zambia Reported As A Success 2Health News:Break-through Discovery Gives Hope For Asthma treatment 2Health News:Environmental Surrounding Affects Human Behaviour 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: